Nuveen California Municipal Value Fund 2 (NYSE:NCB) Plans Monthly Dividend of $0.07

Share on StockTwits

Nuveen California Municipal Value Fund 2 (NYSE:NCB) declared a monthly dividend on Wednesday, December 4th, Wall Street Journal reports. Shareholders of record on Friday, December 13th will be given a dividend of 0.0728 per share on Tuesday, December 31st. This represents a $0.87 dividend on an annualized basis and a yield of 5.48%. The ex-dividend date is Thursday, December 12th. This is a boost from Nuveen California Municipal Value Fund 2’s previous monthly dividend of $0.04.

NYSE NCB traded down $0.11 on Wednesday, reaching $15.95. 300 shares of the company were exchanged, compared to its average volume of 3,842. The business’s fifty day moving average price is $16.32 and its 200 day moving average price is $16.35. Nuveen California Municipal Value Fund 2 has a fifty-two week low of $14.79 and a fifty-two week high of $17.50.

About Nuveen California Municipal Value Fund 2

Nuveen California Municipal Value Fund 2 is a close-ended fixed income mutual fund launched by Nuveen Investments Inc The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in fixed income markets of California. The fund primarily invests its assets in municipal securities.

Featured Article: What is the Difference Between Common Shares and Convertible Shares?

Dividend History for Nuveen California Municipal Value Fund 2 (NYSE:NCB)

Receive News & Ratings for Nuveen California Municipal Value Fund 2 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuveen California Municipal Value Fund 2 and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

New Oriental Education & Tech Grp  Issues  Earnings Results, Beats Expectations By $0.16 EPS
New Oriental Education & Tech Grp Issues Earnings Results, Beats Expectations By $0.16 EPS
Chunghwa Telecom  Issues FY 2019
Pre-Market Earnings Guidance
Chunghwa Telecom Issues FY 2019 Pre-Market Earnings Guidance
Wedbush Increases MacroGenics  Price Target to $16.00
Wedbush Increases MacroGenics Price Target to $16.00
HC Wainwright Reaffirms “Buy” Rating for Interpace Diagnostics Group
HC Wainwright Reaffirms “Buy” Rating for Interpace Diagnostics Group
Cantor Fitzgerald Reaffirms Overweight Rating for Tivity Health
Cantor Fitzgerald Reaffirms Overweight Rating for Tivity Health
GSX Techedu  Now Covered by Analysts at Goldman Sachs Group
GSX Techedu Now Covered by Analysts at Goldman Sachs Group


 
© 2006-2020 Zolmax.